KOMPLEKSNOE LEChENIE INTRAEPITELIAL'NYKh NEOPLAZIY ShEYKI MATKI S PRIMENENIEM PREPARATA NEOVIR


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study including 20 women has evaluated the efficacy of immunomodulating antiviral drug Neovir (sodium oxodihydroacridinilacetate) in the treatment of cervical dysplasia and pre-invasive cervical carcinoma. It was shown that Neovir causes the increase of effector function of T cell immune response, pronounced local reaction expressed by the migration of lymphocytes into the dysplasia focus, and leads to regression of neoplastic changes in the epithelium in this category of patients. The observed efficacy of Neovir determines further evaluation of its use in patients with early neoplastic cervical changes.

Full Text

Restricted Access

About the authors

E. V Bakhidze

References

  1. Munoz N., Bosch F.X., de Sanjos S., et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348(6):518-27.
  2. Chen Z., Schiffman M., Herrero R., et al. Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011;6(5):e20183.
  3. Munoz N., Bosch F.X., de Sanjos S., et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348(6):518-27.
  4. Евстигнеева Л.А., Бахидзе Е.В., Семиглазов В.В. и др. Роль вирусологических факторов в развитии рака шейки матки у молодых женщин // Журнал акушерства и женских болезней 2007. Т. 57. С. 153-54.
  5. Роговская С.И., Шипулина О.Ю., Минкина Г.Н. и др. Эпидемиология ВПЧ-инфекции в России. В кн.: Профилактика рака шейки матки: Руководство для врачей / Под ред. Г.Т. Сухих, В.Н. Прилеепской. М., 2012. С. 30-8.
  6. Zuna R.E., Allen R.A., Moore W.E., et al. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Modern Pathology 2007;20:67-174.
  7. Zhao E.F., Bao L., Li C., Song L., Li Y.L. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. J First Med Univ 2005;25(6):605-09.
  8. Edwards B.K., Brown M.L., Wingo P.A. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment. J Natl Cancer Inst 2005;97(19):1407-27.
  9. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
  10. Jain R., Gupta M.M., Parashari A., et al. Peripheral blood lymphocyte subpopulations in Indian women with cervical intraepithelial neoplasia and invasive cancer an immunocytochemical study using monoclonal antibodies. Cancer Lett 1990;54(1-2):17-20.
  11. Das S., Karim S., Datta Ray C., et al. Peripheral blood lymphocyte subpopulations in patients with cervical cancer. Int J Gynaecol Obstet 2007;98(2):143-46.
  12. Gemignani M., Maiman M., Fruchter R.G., et al. CD4 lymphocytes in women with invasive and preinvasive cervical neoplasia. Gynecol Oncol 1995;59(3):364-69.
  13. Gadducci A., Barsotti C., Cosio S., et al. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 2011;27(8):597-604.
  14. Ho G.Y.F., Burk R.D., Klein S., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Int. J Cancer 1995;87:1365-71.
  15. Trottier H., Mahmud S., Costa M.C., et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006;15(7):1274-80.
  16. Franco E.L., Villa L.L., Sobrinho J.P., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
  17. Moscicki A.B., Shiboski S., Broering J., et al. Natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132(2):277-84.
  18. Ahdieh L., Munoz A., Vlahov D., et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000;151:1148-57.
  19. Scott M., Nakagawa M., Moscicki A.B. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8:209-20.
  20. Kadish AS, Timmins P, Wang Y, et al. Regression of Cervical Intraepithelial Neoplasia and Loss of Human Papillomavirus (HPV) Infection Is Associated with Cell-mediated Immune Responses to an HPV Type 16 E7 Peptide. Cancer Epidemiol Biomarkers 2002;11:483-88.
  21. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by IFN gamma ELISpot in women with cleared or persistent HPV infection. Int J Gynecol Cancer 2009;19(4):508-12.
  22. Gemignani M., Maiman M., Fruchter R.G., et al. CD4 lymphocytes in women with invasive and preinvasive cervical neoplasia. Gynecol Oncol 1995;59(3):364-69.
  23. Steele J.C., Mann C.H., Rookes S., et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005;93:248-59.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies